ARTICLE | Company News
Active Biotech cancer news
July 27, 2015 7:00 AM UTC
Active Biotech will reduce its headcount by 37 (66%) to 19 employees after announcing in April that it would discontinue development of tasquinimod. The Phase III 10TASQ10 trial showed that the oral quinoline-3-carboxamide derivative that binds S100 calcium binding protein A9 ( S100A9; calgranulin B; MRP14) did not extend overall survival in patients with prostate cancer. Active Biotech said the cuts will be implemented by Jan. 1 (see BioCentury, April 20). ...